Cargando…

Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells

The difficulty of glioblastoma treatment makes it a good candidate for novel therapies, such as oncolytic viruses. Vesicular stomatitis virus expressing Lassa virus glycoprotein (Lassa-VSV) showed significant promise in animal models using established glioblastoma cell lines. These experiments were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Teddy E., Puckett, Shelby, Zhang, Kailong, Herpai, Denise M., Ornelles, David A., Davis, John N., van den Pol, Anthony N., Debinski, Waldemar, Lyles, Douglas S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424128/ https://www.ncbi.nlm.nih.gov/pubmed/34514102 http://dx.doi.org/10.1016/j.omto.2021.06.003

Ejemplares similares

MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells
por: Bayne, Robert S., et al.
Publicado: (2020)

Immunogenicity in African Green Monkeys of M Protein Mutant Vesicular Stomatitis Virus Vectors and Contribution of Vector-Encoded Flagellin
por: Westcott, Marlena M., et al.
Publicado: (2018)

Vesicular stomatitis virus nucleocapsids diffuse through cytoplasm by hopping from trap to trap in random directions
por: Holzwarth, George, et al.
Publicado: (2020)

Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
por: Marzi, Andrea, et al.
Publicado: (2015)

Drug Conjugates for Targeting Eph Receptors in Glioblastoma
por: Sharma, Puja, et al.
Publicado: (2020)

Multireceptor targeting of glioblastoma
por: Sharma, Puja, et al.
Publicado: (2020)

Simultaneous targeting of Eph receptors in glioblastoma
por: Ferluga, Sara, et al.
Publicado: (2016)

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
por: Simovic, Boris, et al.
Publicado: (2015)

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer
por: Heiber, Joshua F., et al.
Publicado: (2011)

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
por: Muik, Alexander, et al.
Publicado: (2012)

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Hastie, Eric, et al.
Publicado: (2016)

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines
por: Bridle, Byram W, et al.
Publicado: (2013)

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
por: Bourgeois-Daigneault, Marie-Claude, et al.
Publicado: (2016)

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
por: Nagalo, Bolni Marius, et al.
Publicado: (2020)

A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses
por: Safronetz, David, et al.
Publicado: (2015)

A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs
por: Stein, Derek R., et al.
Publicado: (2019)

Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
por: Naik, Shruthi, et al.
Publicado: (2012)

Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells
por: Garijo, Raquel, et al.
Publicado: (2014)

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells
por: Corredor, Juan C, et al.
Publicado: (2016)

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
por: Melzer, Michael Karl, et al.
Publicado: (2017)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Hydrodynamic characterization of a vesicular stomatitis virus-based oncolytic virus using analytical ultracentrifugation
por: Wawra, Simon, et al.
Publicado: (2023)

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells
por: Goad, Dakota W., et al.
Publicado: (2023)

IL13RA2 targeted alpha particle therapy against glioblastomas
por: Sattiraju, Anirudh, et al.
Publicado: (2017)

Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia
por: Betancourt, Dillon, et al.
Publicado: (2015)

Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models
por: Le Boeuf, Fabrice, et al.
Publicado: (2017)

In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Jenner, Adrianne L, et al.
Publicado: (2021)

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions
por: Holbrook, Molly C., et al.
Publicado: (2021)

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Goad, Dakota W., et al.
Publicado: (2021)

Aphthæ, or Vesicular Stomatitis of the Horse
por: Hutcheon, D.
Publicado: (1898)

The Presence and Potential Role of ALDH1A2 in the Glioblastoma Microenvironment
por: Sanders, Stephanie, et al.
Publicado: (2021)

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
por: Eckert, Elizabeth C., et al.
Publicado: (2019)

Correction: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Publicado: (2021)

Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer
por: Rangsitratkul, Coby, et al.
Publicado: (2022)

RIG‐I‐mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus
por: Zhang, Pengfei, et al.
Publicado: (2022)

Functional Dissection of the Dominant Role of CD55 in Protecting Vesicular Stomatitis Virus against Complement-Mediated Neutralization
por: Asok Kumar, Nisha, et al.
Publicado: (2021)

The synthetic futures of vesicular stomatitis virus
por: Overend, Christopher, et al.
Publicado: (2012)

Association of vesicular stomatitis virus M protein with host plasma membranes and phenotype of temperature sensitive M protein mutants
por: Lyles, D.S., et al.
Publicado: (1988)

Autophagy Gene Activity May Act As a Key Factor for Sensitivity of Tumor Cells to Oncolytic Vesicular Stomatitis Virus
por: Nabizadeh, Arezoo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_923k4cf676q5e23dps3lv602iu